Is ALNY or DXCM cheaper?

On trailing earnings, DXCM is cheaper: ALNY trades at a 66.81 P/E and DXCM at 31.68.

Which has grown faster, ALNY or DXCM?

Over the past five years, ALNY grew revenue faster — ALNY at a 49.67% CAGR versus DXCM at 18.91%.

Is ALNY or DXCM more profitable?

DXCM runs the higher net margin — ALNY at 13.46% versus DXCM at 19.31%.

Which has been the better investment, ALNY or DXCM?

Over the past 10-year, ALNY delivered the higher annualized total return — ALNY at 16.14% versus DXCM at 14.27%. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs DexCom, Inc. (DXCM)

DXCM leads on 10 of 14 compared metrics.

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and DexCom, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 15, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

ALNY

Alnylam Pharmaceuticals, Inc.

$37.46B

$280.59HealthcareDelayed quote: Jul 15, 2026, 11:45 AM EDT

DXCM

DexCom, Inc.

$28.84B

$74.75HealthcareDelayed quote: Jul 15, 2026, 11:45 AM EDT

Total return — ALNY vs DXCM

growth of $100 · dividends reinvested · last 21y

ALNY +3321.7%DXCM +2421.1%ALNY compounded faster

ALNY DXCM

ALNY vs DXCM: by the numbers

•ALNY is the larger company ($37.46B vs $28.84B market cap).
•DXCM trades at the lower earnings multiple (31.68 vs 66.81 P/E).
•DXCM converts more revenue to profit (19.31% vs 13.46% net margin).
•ALNY grew revenue faster over the past five years (49.67% vs 18.91% CAGR).

Which is better, ALNY or DXCM?

Metric tally: ALNY 4 · DXCM 10

It depends on what you're optimizing for:

ValueDXCM(lower P/E)

GrowthALNY(faster 5Y revenue CAGR)

QualityDXCM(higher ROIC)

Metrics side by side

Valuation

Metric	ALNY	DXCM
P/E ratio	66.81	31.68●
Forward P/E	37.91	28.58●
P/S ratio	9.07	6.06●
P/B ratio	36.15	9.87●
PEG ratio	—	0.67
EV / EBITDA	47.64	22.78●
FCF yield	1.65%	4.90%●

Profitability

Metric	ALNY	DXCM
Gross margin	80.89%●	61.84%
Operating margin	17.54%	21.45%●
Net margin	13.46%	19.31%●
ROE	53.68%●	31.47%
ROIC	13.74%	16.61%●

Growth (annualized)

Metric	ALNY	DXCM
Revenue CAGR (5Y)	49.67%●	18.91%
EPS CAGR (5Y)	—	10.31%
FCF CAGR (5Y)	14.35%	43.37%●
Total return CAGR (5Y)	10.55%●	-7.61%

Frequently asked

Which is better, ALNY or DXCM?: It depends on your goal. value: DXCM (lower P/E); growth: ALNY (faster 5Y revenue CAGR); quality: DXCM (higher ROIC). Across all compared metrics, DXCM leads 10 to 4.
Is ALNY or DXCM cheaper?: On trailing earnings, DXCM is cheaper: ALNY trades at a 66.81 P/E and DXCM at 31.68.
Which has grown faster, ALNY or DXCM?: Over the past five years, ALNY grew revenue faster — ALNY at a 49.67% CAGR versus DXCM at 18.91%.
Is ALNY or DXCM more profitable?: DXCM runs the higher net margin — ALNY at 13.46% versus DXCM at 19.31%.
Which has been the better investment, ALNY or DXCM?: Over the past 10-year, ALNY delivered the higher annualized total return — ALNY at 16.14% versus DXCM at 14.27%. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full DXCM analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio DexCom P/E ratio Alnylam Pharmaceuticals dividend yield DexCom dividend yield Alnylam Pharmaceuticals ROE DexCom ROE Alnylam Pharmaceuticals operating margin DexCom operating margin Alnylam Pharmaceuticals revenue growth DexCom revenue growth Alnylam Pharmaceuticals free cash flow DexCom free cash flow

Alnylam Pharmaceuticals & DexCom appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Best 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 15, 2026.